These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 26208714)

  • 1. Erosive esophageal reflux vs. non erosive esophageal reflux: oral findings in 71 patients.
    Deppe H; Mücke T; Wagenpfeil S; Kesting M; Rozej A; Bajbouj M; Sculean A
    BMC Oral Health; 2015 Jul; 15():84. PubMed ID: 26208714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcome of Nissen fundoplication in non-erosive and erosive gastro-oesophageal reflux disease.
    Broeders JA; Draaisma WA; Bredenoord AJ; Smout AJ; Broeders IA; Gooszen HG
    Br J Surg; 2010 Jun; 97(6):845-52. PubMed ID: 20473997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-erosive and erosive gastroesophageal reflux diseases: No difference with regard to reflux pattern and motility abnormalities.
    Martínek J; Benes M; Hucl T; Drastich P; Stirand P; Spicák J
    Scand J Gastroenterol; 2008; 43(7):794-800. PubMed ID: 18584517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of risk factors and clinical responses to proton pump inhibitors in patients with erosive oesophagitis and non-erosive reflux disease.
    Lee ES; Kim N; Lee SH; Park YS; Kim JW; Jeong SH; Lee DH; Jung HC; Song IS
    Aliment Pharmacol Ther; 2009 Jul; 30(2):154-64. PubMed ID: 19392871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More severe upper gastrointestinal symptoms associated with non-erosive reflux disease than with erosive gastroesophageal reflux disease during maintenance proton pump inhibitor therapy.
    Kusano M; Hosaka H; Kawamura O; Kawada A; Kuribayashi S; Shimoyama Y; Yasuoka H; Mizuide M; Tomizawa T; Sagawa T; Sato K; Yamada M
    J Gastroenterol; 2015 Mar; 50(3):298-304. PubMed ID: 24919745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical analysis of recurrence rate and symptom improvement in gastro-esophageal reflux disease patients].
    Jeong YJ; Lee DH; Choi TH; Hwang TJ; Lee BH; Nah JC; Lee SH; Park YS; Hwang JH; Kim JW; Jeong SH; Kim N; Jung HC; Song IS
    Korean J Gastroenterol; 2010 Feb; 55(2):100-8. PubMed ID: 20168056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-erosive reflux disease (NERD), symptomatic and asymptomatic erosive reflux disease (ERD): from hypersensitive to hyposensitive esophagus.
    Hartono JL; Qua CS; Goh KL
    Dig Dis Sci; 2011 Jan; 56(1):90-6. PubMed ID: 20467897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Demographic, clinical, and psychological characteristics of the heartburn groups classified using the Rome III criteria and factors associated with the responsiveness to proton pump inhibitors in the gastroesophageal reflux disease group.
    Lee KJ; Kwon HC; Cheong JY; Cho SW
    Digestion; 2009; 79(3):131-6. PubMed ID: 19307735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Prevalence and Clinical Features of Non-responsive Gastroesophageal Reflux Disease to Practical Proton Pump Inhibitor Dose in Korea: A Multicenter Study.
    Park HJ; Park SH; Shim KN; Kim YS; Kim HJ; Han JP; Kim YS; Bang BW; Kim GH; Baik GH; Kim HH; Park SY; Kim SS
    Korean J Gastroenterol; 2016 Jul; 68(1):16-22. PubMed ID: 27443619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of proton pump inhibitors on autonomic tone in patients with erosive and non-erosive esophagitis.
    Jones EL; Perring S; Khattab A; Allenby-Smith O
    Neurogastroenterol Motil; 2016 May; 28(5):659-64. PubMed ID: 26748487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Acid-suppressive strategy against gastroesophageal reflux diseases and non-erosive reflux diseases: the alternative of proton- pump inhibitors or H2 receptor antagonists].
    Ishino Y; Sugano K
    Nihon Rinsho; 2007 May; 65(5):891-4. PubMed ID: 17511229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acid and bile reflux in erosive reflux disease, non-erosive reflux disease and Barrett's esophagus.
    Hak NG; Mostafa M; Salah T; El-Hemaly M; Haleem M; Abd El-Raouf A; Hamdy E
    Hepatogastroenterology; 2008; 55(82-83):442-7. PubMed ID: 18613384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Esophageal intraluminal baseline impedance differentiates gastroesophageal reflux disease from functional heartburn.
    Kandulski A; Weigt J; Caro C; Jechorek D; Wex T; Malfertheiner P
    Clin Gastroenterol Hepatol; 2015 Jun; 13(6):1075-81. PubMed ID: 25496815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis.
    Weijenborg PW; Cremonini F; Smout AJ; Bredenoord AJ
    Neurogastroenterol Motil; 2012 Aug; 24(8):747-57, e350. PubMed ID: 22309489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superficial Esophageal Mucosal Afferent Nerves May Contribute to Reflux Hypersensitivity in Nonerosive Reflux Disease.
    Woodland P; Shen Ooi JL; Grassi F; Nikaki K; Lee C; Evans JA; Koukias N; Triantos C; McDonald SA; Peiris M; Aktar R; Blackshaw LA; Sifrim D
    Gastroenterology; 2017 Nov; 153(5):1230-1239. PubMed ID: 28734832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Precise role of acid in non-erosive reflux disease.
    Wang C; Hunt RH
    Digestion; 2008; 78 Suppl 1():31-41. PubMed ID: 18832838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenesis of proton-pump inhibitor-refractory non-erosive reflux disease according to multichannel intraluminal impedance-pH monitoring.
    Kohata Y; Fujiwara Y; Machida H; Okazaki H; Yamagami H; Tanigawa T; Watanabe K; Watanabe T; Tominaga K; Arakawa T
    J Gastroenterol Hepatol; 2012 Apr; 27 Suppl 3():58-62. PubMed ID: 22486873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histomorphological differentiation of non-erosive reflux disease and functional heartburn in patients with PPI-refractory heartburn.
    Kandulski A; Jechorek D; Caro C; Weigt J; Wex T; Mönkemüller K; Malfertheiner P
    Aliment Pharmacol Ther; 2013 Sep; 38(6):643-51. PubMed ID: 23895770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Underlying Mechanisms and Management of Refractory Gastroesophageal Reflux Disease].
    Lee KJ
    Korean J Gastroenterol; 2015 Aug; 66(2):70-4. PubMed ID: 26289239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Halitosis and tongue coating in patients with erosive gastroesophageal reflux disease versus nonerosive gastroesophageal reflux disease.
    Kislig K; Wilder-Smith CH; Bornstein MM; Lussi A; Seemann R
    Clin Oral Investig; 2013 Jan; 17(1):159-65. PubMed ID: 22437377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.